
TOI Stock Forecast & Price Target
TOI Analyst Ratings
Bulls say
The Oncology Institute Inc. is strategically positioned for future growth as indicated by its strong revenue growth rates of 24%, 28%, and 21% year-over-year from 2022 to 2024, driven by an increased number of clinics under management. The anticipated partnership with Helios is expected to enhance margins significantly by 2026 and 2027, further supported by the overall growth in the U.S. oncology market projected at a 10%+ CAGR. Additionally, the company's focus on expanding its dispensary segment and bolstering its presence in high-value markets like Nevada and Florida contributes to a positive long-term outlook for earnings and sustainable growth.
Bears say
The Oncology Institute Inc. has recently experienced significant declines in revenue contribution, particularly with HUM's share dropping from 20% to less than 10%. Furthermore, the company's gross margins have been negatively impacted by contract losses in 2024, combined with heightened pressures as new contracts are anticipated to scale in the upcoming years. The operational challenges are compounded by decreasing dispensary margins due to the elimination of DIR fees and a stagnant growth trend in patient services that is well below the industry average.
This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.
TOI Analyst Forecast & Price Prediction
Start investing in TOI
Order type
Buy in
Order amount
Est. shares
0 shares